Literature DB >> 17167833

Functional significance of erythropoietin receptor on tumor cells.

Kodetthoor-B Udupa1.   

Abstract

Erythropoietin (Epo) is the regulator of red blood cell formation. Its receptor (EpoR) is now found in many cells and tissues of the body. EpoR is also shown to occur in tumor cells and Epo enhances the proliferation of these cells through cell signaling. EpoR antagonist can reduce the growth of the tumor in vivo. In view of our current knowledge of Epo, its recombinant forms and receptor, use of Epo in cancer patients to enhance the recovery of hematocrit after chemotherapy treatment has to be carefully evaluated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167833      PMCID: PMC4087590          DOI: 10.3748/wjg.v12.i46.7460

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

Review 1.  The cellular biology of erythropoietin receptors.

Authors:  Terry Lappin
Journal:  Oncologist       Date:  2003

Review 2.  Erythropoietin.

Authors:  E D Zanjani; J L Ascensao
Journal:  Transfusion       Date:  1989-01       Impact factor: 3.157

Review 3.  Erythropoietin in health and disease.

Authors:  K U Eckardt; C Bauer
Journal:  Eur J Clin Invest       Date:  1989-04       Impact factor: 4.686

4.  On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action.

Authors:  E Goldwasser; C K Kung; J Eliason
Journal:  J Biol Chem       Date:  1974-07-10       Impact factor: 5.157

5.  Erythropoietin stimulates proliferation of human renal carcinoma cells.

Authors:  C Westenfelder; R L Baranowski
Journal:  Kidney Int       Date:  2000-08       Impact factor: 10.612

6.  Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors.

Authors:  K Sawada; S B Krantz; C H Dai; S T Koury; S T Horn; A D Glick; C I Civin
Journal:  J Cell Physiol       Date:  1990-02       Impact factor: 6.384

7.  Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma.

Authors:  Geza Acs; Paul J Zhang; Timothy R Rebbeck; Peter Acs; Ajay Verma
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

8.  Erythropoietin/erythropoietin-receptor system as an angiogenic factor in chemically induced murine hepatic tumors.

Authors:  Kiyoshi Nakamatsu; Yasumasa Nishimura; Minoru Suzuki; Shuichi Kanamori; Osamu Maenishi; Yoshiko Yasuda
Journal:  Int J Clin Oncol       Date:  2004-06       Impact factor: 3.402

9.  Functional significance of erythropoietin receptor expression in breast cancer.

Authors:  Murat O Arcasoy; Khalid Amin; Aysen F Karayal; Shu-Chuan Chou; James A Raleigh; Mahesh A Varia; Zishan A Haroon
Journal:  Lab Invest       Date:  2002-07       Impact factor: 5.662

10.  Erythropoietin regulates tumour growth of human malignancies.

Authors:  Yoshiko Yasuda; Yoshihiko Fujita; Takuya Matsuo; Satoshi Koinuma; Satoshi Hara; Akira Tazaki; Mie Onozaki; Mitsuhiro Hashimoto; Terunaga Musha; Kazuhiro Ogawa; Hiroyoshi Fujita; Yukio Nakamura; Hitoshi Shiozaki; Hiroshi Utsumi
Journal:  Carcinogenesis       Date:  2003-04-24       Impact factor: 4.944

View more
  5 in total

Review 1.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

2.  Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

Authors:  Milljae Shin; Doopyo Hong; Zhengyun Zhang; You Min Kim; Wookjong Lee; Jae-Won Joh; Sung-Joo Kim
Journal:  HPB (Oxford)       Date:  2013-03-15       Impact factor: 3.647

Review 3.  Erythropoietin and cancer: the unintended consequences of anemia correction.

Authors:  Nataša Debeljak; Peter Solár; Arthur J Sytkowski
Journal:  Front Immunol       Date:  2014-11-11       Impact factor: 7.561

4.  Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer.

Authors:  Chen Ye; Guang-Hua Chen; Xin Chen; Sheng-Fei Qin; Min-Feng Shi; Tie Zhou
Journal:  Asian J Androl       Date:  2020 Jul-Aug       Impact factor: 3.285

5.  Proof-of-concept study on improved efficacy of rHuEPO administered as a long-term infusion in rats.

Authors:  Damian Szczesny; Katarzyna Mołoniewicz; Michał J Markuszewski; Paweł Wiczling
Journal:  Pharmacol Rep       Date:  2020-08-03       Impact factor: 3.024

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.